

FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3

proTGFβ1 wild-type C4S: Cys4→Ser mutation







FIG. 4A




FIG. 4C




FIG. 4B




FIG. 5

	TGFβ1	TGFβ2	TGFβ3
C2	< 1 pM	No binding	15.2 nM
C3	< 1 pM	23.4 nM	5.6 nM
C4	< 1 pM	< 1 pM	18.7 nM
C5	< 1 pM	< 1 pM	< 1 pM
C6	< 1 pM	1.7 nM	< 1 pM
C1	< 1 pM	2.8 nM	< 1 pM




FIG. 6B Titration Curves : Fc Capture – mAb – Ag




FIG. 7A




FIG. 7B






FIG. 7C: Inhibition of LTBP1-proTGFβ1 activation (LN229 assay)



Inhibition of GARP and LRRC33 complex by Ab2 is in Figs. 7A and 7B.

FIG. 7D: Inhibition of GARP-proTGFβ1 activation (SW480b6 assay)

Ab1



Ab3






FIG. 7E: Inhibition of LRRC33-proTGF β 1 activation (SW480b6 assay)Ab1Ab3

FIG. 7F




FIG. 7G

Ab1




FIG. 7H

Ab2




FIG. 8: Inhibition of protease-dependent activation of TGFβ1




FIG. 9A






FIG. 9B



* P < 0.05 (two-tailed T test)

FIG. 10A

mCSF Macrophages are uniformly ‘M2’



PBMC from healthy donors
CD14+ immunomagnetic selection = monocytes
~1 week culture with 10% human serum + GMCSF or MCSF
To induce various M2 macrophages: 2-3 days additional culture with: M2c: IL10&TGFb, M2d: IL6

CD163 – hemoglobin scavenger receptor
CD206 – Mannose Receptor

FIG. 10B

mCSF macrophages uniformly express LRRC33





FIG. 10C

Robust LRRC33 expression on MCSF macrophages






FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 12E




FIG. 12F




FIG. 12G




FIG. 12H






FIG. 12J



* P < 0.05; two-tailed T-test vs. IgG

FIG. 12I



Collagen Volume Fraction: Composite




FIG. 12K





FIG. 13A: Effects of Ab3 in UUO

FIG. 13B




* P < 0.05 One-way ANOVA with Dunnett's post hoc test (vs. IgG control group)

** P < 0.01

*** P < 0.001


FIG. 13C



* P < 0.05
** P < 0.01
*** P < 0.001

One-way ANOVA with Dunnett's post hoc test (vs. IgG control group)

FIG. 14



* P < 0.0001 (One-way ANOVA vs. IgG)

FIG. 15: Alport Study Target Engagement
pSmad2/3 : Smad2/3 Ratio




FIG. 16




FIG. 17
Effects of Ab3 on Survival in
Murine EMT6 Tumor Model




FIG. 18A




FIG. 18B




FIG. 18D




FIG. 18C




FIG. 18E




FIG. 18F Heart valve (valvulopathy)




FIG. 19A




FIG. 19B




FIG. 20 Tonic TGFβ signaling in homeostatic rat BAL cells





FIG. 21A

TGF β isoform expression vs. normal comparator (by cancer type)

Indications approved for PD1/PDL1
therapy listed in **bold**

FIG. 21B Percentage of tumors expressing TGFβ isoforms, by cancer type




FIG. 21C

TGFβ isoform expression in individual tumor samples, by cancer type




FIG. 21D TGFβ isoform expression in mouse syngeneic cancer cell model lines




FIG. 22 Pan-TGF β Antibody Data from 1-Week Safety Study
Heart Example, microscopic findings

Test article	PBS					pan-TGF β Ab					100				
	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5
Dose (mg/kg)															
Animals/group															
Myocardium degeneration/necrosis															x
Hemorrhage, myocardium															x
Hemorrhage, valve															x
Hyperplasia, atrium															x
Hyperplasia, valve endothelium															x
Hyperplasia, valve stroma															x
Mixed cell infiltrate, atrium															x
Mixed cell infiltrate, base															x
Mixed cell infiltrate, coronary artery															x
Mixed cell infiltrate, valve															x
Necrosis with hemorrhage, coronary artery															x
Necrosis/inflammatory cell infiltrate, cardiomyocyte															x
Valvulopathy															x

Legend:

Unremarkable:	
Minimal:	
Slight:	
Moderate:	
Mortality:	x